Protara Therapeutics (TARA) Competitors

$5.30 +0.10 (+1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$5.25 -0.05 (-1.02%)

As of 06:41 PM Eastern

TARA vs. CMPS, URGN, COLL, DBVT, and EVO

Should you buy Protara Therapeutics stock or one of its competitors? MarketBeat compares Protara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protara Therapeutics include Compass Pathways (CMPS), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), DBV Technologies (DBVT), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry.

How does Protara Therapeutics compare to Compass Pathways?

Protara Therapeutics (NASDAQ:TARA) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Protara Therapeutics presently has a consensus price target of $24.50, indicating a potential upside of 362.26%. Compass Pathways has a consensus price target of $20.64, indicating a potential upside of 94.32%. Given Protara Therapeutics' higher possible upside, research analysts clearly believe Protara Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Protara Therapeutics' return on equity of -36.38% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-36.38%	-33.81%
Compass Pathways	N/A	-192.95%	-61.31%

In the previous week, Compass Pathways had 8 more articles in the media than Protara Therapeutics. MarketBeat recorded 12 mentions for Compass Pathways and 4 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.22 beat Compass Pathways' score of 0.86 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protara Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Protara Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market.

Summary

Protara Therapeutics and Compass Pathways tied by winning 7 of the 14 factors compared between the two stocks.

How does Protara Therapeutics compare to Urogen Pharma?

Protara Therapeutics (NASDAQ:TARA) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Protara Therapeutics presently has a consensus price target of $24.50, indicating a potential upside of 362.26%. Urogen Pharma has a consensus price target of $36.67, indicating a potential upside of 23.54%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Protara Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Urogen Pharma had 16 more articles in the media than Protara Therapeutics. MarketBeat recorded 20 mentions for Urogen Pharma and 4 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.22 beat Urogen Pharma's score of 0.50 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-36.38%	-33.81%
Urogen Pharma	-94.83%	N/A	-62.85%

Protara Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Protara Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Urogen Pharma	$140.49M	10.29	-$153.49M	-$2.75	N/A

Summary

Protara Therapeutics beats Urogen Pharma on 9 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Collegium Pharmaceutical?

Protara Therapeutics (NASDAQ:TARA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Collegium Pharmaceutical had 6 more articles in the media than Protara Therapeutics. MarketBeat recorded 10 mentions for Collegium Pharmaceutical and 4 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.22 beat Collegium Pharmaceutical's score of 0.54 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Collegium Pharmaceutical has a net margin of 9.41% compared to Protara Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-36.38%	-33.81%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Collegium Pharmaceutical has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Collegium Pharmaceutical	$796.33M	1.42	$62.87M	$2.04	17.07

38.1% of Protara Therapeutics shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Protara Therapeutics presently has a consensus price target of $24.50, indicating a potential upside of 362.26%. Collegium Pharmaceutical has a consensus price target of $57.50, indicating a potential upside of 65.09%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Protara Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Protara Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to DBV Technologies?

Protara Therapeutics (NASDAQ:TARA) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Protara Therapeutics and Protara Therapeutics both had 4 articles in the media. Protara Therapeutics' average media sentiment score of 1.22 beat DBV Technologies' score of 0.47 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protara Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Protara Therapeutics' return on equity of -36.38% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-36.38%	-33.81%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

DBV Technologies is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 1.4% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Protara Therapeutics presently has a consensus price target of $24.50, indicating a potential upside of 362.26%. DBV Technologies has a consensus price target of $40.25, indicating a potential upside of 102.87%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Protara Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

Protara Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, meaning that its share price is 196% less volatile than the broader market.

Summary

Protara Therapeutics beats DBV Technologies on 11 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Evotec?

Evotec (NASDAQ:EVO) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Evotec has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Protara Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Protara Therapeutics	N/A	-36.38%	-33.81%

5.8% of Evotec shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Protara Therapeutics has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$745.04M	1.30	-$117.12M	N/A	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

In the previous week, Evotec had 14 more articles in the media than Protara Therapeutics. MarketBeat recorded 18 mentions for Evotec and 4 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 1.22 beat Evotec's score of 0.42 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evotec currently has a consensus price target of $7.00, indicating a potential upside of 157.35%. Protara Therapeutics has a consensus price target of $24.50, indicating a potential upside of 362.26%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Protara Therapeutics beats Evotec on 9 of the 14 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARA vs. The Competition

Export

Metric	Protara Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$291.82M	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-4.02	19.11	20.89	25.59
Price / Sales	N/A	280.24	522.17	62.83
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	1.39	4.35	9.86	6.70
Net Income	-$57.44M	$72.19M	$3.55B	$333.77M
7 Day Performance	-1.30%	-0.62%	-0.32%	0.45%
1 Month Performance	3.31%	0.22%	1.33%	4.06%
1 Year Performance	69.33%	46.24%	41.10%	36.24%

Protara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARA Protara Therapeutics	3.0532 of 5 stars	$5.30 +1.9%	$24.50 +362.3%	+61.5%	$291.82M	N/A	N/A	30	Positive News Earnings Report Analyst Forecast
CMPS Compass Pathways	4.0923 of 5 stars	$9.52 +5.7%	$20.45 +114.9%	+181.0%	$1.16B	N/A	N/A	120	Trending News Earnings Report Analyst Forecast Gap Down
URGN Urogen Pharma	3.5655 of 5 stars	$23.29 +1.3%	$34.13 +46.5%	+205.1%	$1.12B	$109.79M	N/A	200	Earnings Report Analyst Forecast Analyst Revision
COLL Collegium Pharmaceutical	2.8134 of 5 stars	$34.58 +0.8%	$53.40 +54.4%	+17.0%	$1.11B	$780.57M	20.22	210	Earnings Report
DBVT DBV Technologies	2.9271 of 5 stars	$19.47 -2.0%	$40.25 +106.7%	+78.3%	$1.11B	$5.64M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protara Therapeutics (TARA) Competitors

TARA vs. CMPS, URGN, COLL, DBVT, and EVO

How does Protara Therapeutics compare to Compass Pathways?

Summary

How does Protara Therapeutics compare to Urogen Pharma?

Summary

How does Protara Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Protara Therapeutics compare to DBV Technologies?

Summary

How does Protara Therapeutics compare to Evotec?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protara Therapeutics (TARA) Competitors

TARA vs. CMPS, URGN, COLL, DBVT, and EVO

How does Protara Therapeutics compare to Compass Pathways?

Do analysts recommend TARA or CMPS?

Is TARA or CMPS more profitable?

Does the media favor TARA or CMPS?

Do insiders and institutionals believe in TARA or CMPS?

Which has stronger earnings & valuation, TARA or CMPS?

Which has more risk and volatility, TARA or CMPS?

Summary

How does Protara Therapeutics compare to Urogen Pharma?

Do institutionals and insiders believe in TARA or URGN?

Do analysts recommend TARA or URGN?

Does the media refer more to TARA or URGN?

Is TARA or URGN more profitable?

Which has more volatility & risk, TARA or URGN?

Which has higher earnings and valuation, TARA or URGN?

Summary

How does Protara Therapeutics compare to Collegium Pharmaceutical?

Does the media refer more to TARA or COLL?

Is TARA or COLL more profitable?

Which has better earnings & valuation, TARA or COLL?

Do insiders & institutionals believe in TARA or COLL?

Do analysts recommend TARA or COLL?

Which has more risk & volatility, TARA or COLL?

Summary

How does Protara Therapeutics compare to DBV Technologies?

Does the media refer more to TARA or DBVT?

Is TARA or DBVT more profitable?

Which has better earnings & valuation, TARA or DBVT?

Do insiders & institutionals believe in TARA or DBVT?

Do analysts recommend TARA or DBVT?

Which has more risk & volatility, TARA or DBVT?

Summary

How does Protara Therapeutics compare to Evotec?

Which has more risk & volatility, EVO or TARA?

Is EVO or TARA more profitable?

Do institutionals & insiders believe in EVO or TARA?

Which has stronger valuation & earnings, EVO or TARA?

Does the media prefer EVO or TARA?

Do analysts rate EVO or TARA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools